Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $130.8 million.

  • Enanta Pharmaceuticals' Non-Current Assets rose 6251.41% to $130.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $365.7 million, marking a year-over-year increase of 1012.07%. This contributed to the annual value of $76.4 million for FY2025, which is 52.6% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Non-Current Assets is $130.8 million, which was up 6251.41% from $76.4 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Non-Current Assets high stood at $130.8 million for Q4 2025, and its period low was $38.2 million during Q4 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Non-Current Assets had a median value of $74.3 million in 2022 and averaged $77.2 million.
  • Within the past 5 years, the most significant YoY rise in Enanta Pharmaceuticals' Non-Current Assets was 22402.91% (2021), while the steepest drop was 6430.43% (2021).
  • Over the past 5 years, Enanta Pharmaceuticals' Non-Current Assets (Quarter) stood at $113.6 million in 2021, then tumbled by 43.83% to $63.8 million in 2022, then plummeted by 40.16% to $38.2 million in 2023, then soared by 110.75% to $80.5 million in 2024, then surged by 62.51% to $130.8 million in 2025.
  • Its last three reported values are $130.8 million in Q4 2025, $76.4 million for Q3 2025, and $78.3 million during Q2 2025.